Has biopsy-proven, previously untreated, histologically confirmed cluster of differentiation (CD)19-positive and CD20-positive classical follicular lymphoma (FL), with Ann Arbor Stage II-IV disease and a Follicular Lymphoma International Prognostic Index (FLIPI) score of 2-5.
Has radiographically measurable disease per the Lugano Response Criteria.
Has provided a newly obtained core or excisional biopsy or archival tissue of a tumor lesion not previously irradiated.
If human immunodeficiency virus (HIV)-positive, has well-controlled HIV on antiretroviral therapy (ART).
If hepatitis B surface antigen (HBsAg)-positive, has undetectable hepatitis B virus (HBV) viral load and has received HBV antiviral therapy for at least 4 weeks and will continue it.
If history of hepatitis C virus (HCV) infection, has undetectable HCV viral load.
You may not be if
Has received prior systemic anticancer therapy or radiotherapy for FL.
Has follicular large B-cell lymphoma or any other subtype of FL other than classical FL.
Has FL that has transformed into a more aggressive type of lymphoma.
History or presence of clinically relevant central nervous system (CNS) diseases.
Has history of serious cardiovascular and cerebrovascular diseases.
Is HIV-infected with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
Has known active CNS lymphoma or involvement.
Has an active autoimmune disease that has required systemic treatment in the past 2 years.
Has active infection requiring systemic therapy.
Has chronic liver disease, including liver cirrhosis of Child-Pugh class B or C.
Has not adequately recovered from major surgery or has ongoing surgical complications.
Clareo Health | A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
